期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

唑来膦酸对内分泌治疗绝经前乳腺癌患者所致骨丢失的效果观察 被引量：1

下载PDF
导出
摘要 目的观察唑来膦酸对戈舍瑞林与芳香化酶抑制剂联合治疗绝经前转移性乳腺癌患者所致骨丢失的临床效果和安全性,为临床应用提供参考。方法收集90例在我院乳腺科接受戈舍瑞林联合芳香化酶抑制剂治疗的绝经前转移性乳腺癌患者的临床资料,分为三组,A组(30例)和B组(30例)在戈舍瑞林联合芳香化酶抑制剂治疗的同时使用唑来膦酸,疗程分别为5年和2年;C组(30例)在戈舍瑞林联合芳香化酶抑制剂治疗期间未使用唑来膦酸。所有患者通过双能X线骨密度测量仪检测各时间点各组骨密度值,使用视觉模拟评分法进行肢体骨痛评定,观察记录骨质疏松性骨折的发生率。结果随访60个月,A组患者各时间点骨密度均较C组升高(P<0.05):A组患者在治疗第48,60个月骨密度较B组患者升高(P<0.05):四肢疼痛视觉模拟评分A组低于B组和C组(P<0.05):A组患者骨质疏松性骨折的发生率显著低于B组和C组(P<0.05)。结论绝经前转移性乳腺癌患者行戈舍瑞林联合芳香化酶抑制剂治疗期间,早期足疗程应用唑来膦酸可减少骨量丢失和相关骨折发生,缓解骨痛。
作者 宋亚琪 牛凤玲 林婷 王秀丽 段韩立
机构地区 唐山市人民医院乳腺中心
出处 《贵州医药》 CAS 2016年第8期830-832,共3页 Guizhou Medical Journal
基金 河北省卫生厅科研基金资助项目[编号:13010520152128]
关键词 唑来膦酸 绝经前乳腺癌 戈舍瑞林 芳香化酶抑制剂 骨密度
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1孙伟玲(综述),赵艳滨(综述),蔡莉(审校).乳腺癌药物卵巢去势新进展[J].实用肿瘤学杂志,2014,28(1):81-84. 被引量：6
  • 2杨婷婷,王涛,边莉,姜航,张少华,吴世凯,江泽飞.卵巢功能去势联合芳香化酶抑制剂治疗绝经前转移性乳腺癌的临床研究[J].临床肿瘤学杂志,2013,18(6):521-524. 被引量：6
  • 3刘芊,王涛,江泽飞,曾敏,张少华,吴世凯.药物性卵巢去势联合阿那曲唑治疗绝经前转移性乳腺癌患者的临床研究[J].肿瘤研究与临床,2012,24(6):392-394. 被引量：13
  • 4Yao S,Xu B,Li Q,et al.Goserelin pius letrozole as first-line or second-line hormonal treatment in permenopausal patients with advanced breast cancer[J].Endocr J,2011,58(6):509-516.
  • 5Servitja S,Nogras X,Prieto AD,et al,Bone health in a prospective cohort of postmenopausal women receiving aromatase inhiditors for early breast cancer[J].Breast,2012,21(1):95-101.
  • 6Brufsky AM,Bosserman LD,Caradonna RR,et al.Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in pqst menopausalwomen with early breast cancer receiving adjuvant letrozole:ZFAST study 36-minths follow-up results[J].Clin Breast Cancer,2009,9(2):77-85.
  • 7陈晓霞.唑来膦酸联合化疗治疗胃癌骨转移性疼痛的护理体会[J].贵州医药,2015,39(5):472-473. 被引量：4
  • 8Gnant M,Mlineritsch B,Stoeger H,et al.Adjuvant endocrine therapy plus zoledronic acid in oremenopausal women with early stage breast cancer:62month follow-up from the ABCSG-12randomised trail[J].Lancet Oncol,2011,12(7):631-641.
  • 9Kalder M,Kyvernitakis I,Albert U S,et al.Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopaLisal women with breast cancer treatment-induced bone loss:results of the ProBONEⅡsubstudy[J].Osteoporosis International,2015,26(1):353-360.
  • 10Diel IJ,Berger R,Grota KA.Adverse effects of bisphosphonates:current issues[J]J Support Onco1,2007,5(10):475-482.

二级参考文献17

  • 1张志强,江泽飞,宋三泰,王涛,申戈,于静新,张少华,闫敏.诺雷德联合瑞宁得治疗绝经前复发转移性乳腺癌的临床研究[J].癌症进展,2004,2(2):127-130. 被引量：17
  • 2Hiroyuki Kawabata,Ichiro Oda,Haruhisa Suzuki,Satoru Nonaka,Shigetaka Yoshinaga,Hitoshi Katai,Hirokazu Taniguchi,Ryoji Kushima,Yutaka Saito.Bone metastasis from early gastric cancer following non-curative endoscopic submucosal dissection[J].World Journal of Gastroenterology,2013,19(30):5016-5020. 被引量：2
  • 3Celio L, Martinetti A, Ferrari L, et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone an- alog alone or in combination with an aromatase inhibitor: A com- parative endocrine study[ J ]. Anticancer Res, 1999, 19 ( 3B ) : 2261 - 2268.
  • 4Yao S,Xu B, Li Q, et al. Goserelin plus letrozole as first-line or second-line hormonal treatment in premenopausal patients with advanced breast cancer [ J ]. Endocr J,2011,58 (6) :509 - 516.
  • 5Torrisi R, Bagnardi V, Pruneri G, et al. Antitumour and biologi- cal effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer[ J ]. Br J Cancer, 2007,97 (6) :802 - 808.
  • 6Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus meges- trol acetate in the treatment of postmenopausal women with ad- vanced breast carcinoma results of a survival update based on a combined analysis of data from two mature phase In trials. Arimi- dex Study Group[J]. Cancer,1998, 83(6) :1142 - 1152.
  • 7Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase iii study of the international letrozole breast cancer group[ J]. J Clin Oncol, 2001, 19(10) :2596 -2606.
  • 8Kvinnsland S, Anker G, Dirix LY, et al. High activity and tolera- bility demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment[J]. Eur J Cancer, 2000, 36(8) :976 -982.
  • 9Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trail of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole [ J]. Eur J Cancer, 2003,39(16) :2318 - 2327.
  • 10Cheung KL, Agrawal A, Folkerd E, et al. Suppression of ovari- an function in combination with an aromatase inhibitor as treat- ment for advanced breast cancer in pre-menopansal women [ J ]. Eur J Cancer, 2010,46 ( 16 ) : 2936 - 2942.

共引文献21

同被引文献12

引证文献1

二级引证文献1

贵州医药
2016年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部